• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

COPD Insights: 6 Study Briefs for Primary Care

Slideshow

Second-hand smoke and COPD, optimal cutoff for COPD diagnosis, impact of exercise on COPD risk, and 3 more new findings, at-a-glance.

Related Content
Roflumilast Associated with Increase in 5-Year Mortality Risk in Patients with COPD / Image credit: ©Oleksandr/AdobeStock

Roflumilast Associated with Increase in 5-Year Mortality Risk in Patients with COPD

Brooke McCormick
September 6th 2024
Article

In a large study of patients with COPD, a small increase in 5-year all-cause mortality risk was observed among those using roflumilast.

FDA Approves Ensifentrine for Maintenance Treatment of COPD in Adults: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves Ensifentrine for Maintenance Treatment of COPD in Adults: Daily Dose

Sydney Jennings
July 8th 2024
Article

Your daily dose of the clinical news you may have missed.

FDA Decision on Dupilumab for COPD Pushed Back to September 2024

FDA Decision on Dupilumab for COPD Pushed Back to September 2024

Grace Halsey
May 31st 2024
Article

FDA has no concerns about the "approvability" of dupilumab for the new indication but needs additional time to review phase 3 data it requested early in May.

Tezepelumab Found to Reduce Rate of COPD Exacerbations in Persons with Wide Range of Blood Eosinophil Levels: Daily Dose / image credit: ©New Africa/AdobeStock

Tezepelumab Found to Reduce Rate of COPD Exacerbations in Persons with Wide Range of Blood Eosinophil Levels: Daily Dose

Sydney Jennings
May 28th 2024
Article

Your daily dose of the clinical news you may have missed.

Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes ©Crystal Light/stock.adobe.com

Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes

Grace Halsey
May 22nd 2024
Article

Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.

Dupilumab reduced annualized rate of exacerbations in COPD in NOTUS Surya P Bhatt, MD, MSPH Courtesy University of Alabama

Dupilumab in Replicate Phase 3 Trial Significantly Reduces COPD Exacerbations, Improves Lung Function, with PDUFA Date in Sight

Grace Halsey
May 21st 2024
Article

Dupilumab reduced COPD exacerbations by 34% in adults with uncontrolled symptoms and evidence of T2 inflammation, and significantly improved lung function.

© 2024 MJH Life Sciences

All rights reserved.